Cameroon
Tuberculosis profile
| High HIV burden |
Population  2012 22 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 6.4 (2.7–12) 29 (12–54)
Mortality (HIV+TB only) 7.7 (6.5–9.3) 35 (30–43)
Prevalence  (includes HIV+TB) 69 (33–120) 319 (153–544)
Incidence  (includes HIV+TB) 52 (43–61) 238 (197–283)
Incidence (HIV+TB only) 19 (16–23) 88 (73–104)
Case detection, all forms (%) 48 (40–58)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 15 016 (63) Relapse 1 058 (65)
Smear-negative 5 204 (22) Treatment after failure 158 (10)
Smear-unknown / not done 0 (0) Treatment after default 400 (25)
Extrapulmonary 3 524 (15) Other 0 (0)
Other 0 (0)      
Total new 23 744   Total retreatment 1 616  
           
Other (history unknown) 0        
Total new and relapse 24 802   Total cases notified 25 360  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.5    
Age < 15 292    
Laboratories 2012
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 0.9
Drug susceptibility testing (per 5 million population) 0.5
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 80   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 78  
Retreatment 70  
TB/HIV 2012 Number (%)
TB patients with known HIV status 20 810 (82)
HIV-positive TB patients 7 747 (37)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 6 432 (83)
HIV-positive TB patients on antiretroviral therapy (ART) 4 261 (55)
HIV-positive people screened for TB 11 951  
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.5 (0.01–5) 10 (3.5–17)
MDR-TB cases among notified pulmonary
TB cases
510 (2–1 000) 160 (57–270)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 0 (0%) 80 (5%) 80
Laboratory-confirmed MDR-TB cases 0 71 153
Patients started on MDR-TB treatment     76
Financing TB control 2013
National TB programme budget (US$ millions) 6.7
% Funded domestically 15%
% Funded internationally 41%
% Unfunded 44%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data